Since the bone marrow is sufficient to generate SCD, and PCSK9 is produced primarily by non-hematopoietic cells, the BMT strategy is convenient to test the effects of lipid lowering in SCD. The gene discussed is PCSK9; the disease is Schnyder corneal dystrophy.